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Tuberculosis remains a major public health problem, especially in developing countries. Brazil presents 
the largest number of cases in Latin America and is among the 22 countries considered priorities by the 
World Health Organization (WHO). The Rio de Janeiro state has the largest number of cases registered in 
the country. The treatment of patients, commonly, makes use of the drugs isoniazid and rifampicin for six 
months. This study aimed to develop and validate an electroanalytical methodology, using the technique 
of differential pulse voltammetry for the determination of these drugs in the associated form, in order 
to evaluate the quality of medicines distributed in the state of Rio de Janeiro. The potential reduction 
for the isoniazid and rifampicin were -1.10 and -0.90 V. The developed and validated electroanalytical 
method presented a linear range of 0.25 to 1.25 mg/L to isoniazid, limits of detection and quantification 
of 0.05 and 0.14 mg/L, and recovery of 98.2 ± 0.4%; a tracking linear of 0.40 to 2.00 mg/L for rifampicin, 
with limits of detection and quantification of 0.07 and 0.19 mg/L and recovery of 95.8 ± 0.6%. Six lots 
of medicines from two pharmaceutical companies were analyzed. Only one of the samples showed 
unsatisfactory levels of rifampicin.
Uniterms: Isoniazid. Rifampicin. Tuberculosis/treatment. Tuberculostatics/quantitative analysis. 
Differential pulse voltammetry.
A tuberculose continua sendo um importante problema de saúde pública, especialmente em países em 
desenvolvimento. O Brasil apresenta o maior número de casos da América Latina, estando entre os 22 
países considerados prioritários nas ações de controle da doença pela Organização Mundial da Saúde 
(OMS). No Brasil, o Rio de Janeiro é o estado com o maior número de casos registrados no país. O 
tratamento de doentes com tuberculose faz uso dos fármacos isoniazida e rifampicina durante seis meses. 
O presente trabalho objetivou desenvolver e validar metodologia eletroanalítica, utilizando a técnica de 
voltametria de pulso diferencial, para a determinação desses dois princípios ativos na forma associada 
e avaliar a qualidade dos medicamentos distribuídos no estado do Rio de Janeiro. Os potenciais de 
redução para a isoniazida e rifampicina foram respectivamente -1,10 e -0,90 V. O método eletroanalítico 
desenvolvido e validado apresentou para a isoniazida faixa linear de 0,25 a 1,25 mg/L, limites de detecção 
e quantificação de 0,05 e 0,14 mg/L e recuperação de 98,2 ± 0,4%; para a rifampicina faixa linear de 
0,40 a 2,00 mg/L, limites de detecção e quantificação de 0,07 e 0,19 mg/L e recuperação de 95,8 ± 0,6%. 
Foram analisados 6 lotes de medicamentos de dois laboratórios farmacêuticos. Apenas uma das amostras 
apresentou teor de rifampicina insatisfatório.
Unitermos: Isoniazida/determinação. Rifampicina/determinação. Tuberculostáticos/análise quantitativa. 
Tuberculose/tratamento. Voltametria de pulso diferencial/utilização.
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INTRODUCTION
The World Health Organization (WHO), since 1993, 
stated alert status in the world respecting to tuberculosis, 
which represents a great challenge in terms of world 
public health. A third of human population is infected by 
Mycobacterium tuberculosis and great proportion of them 
could develop and transmit the disease for the community 
(Kritisk et al., 2007). According to World Health Organi-
zation, it is estimated that about 100 million of people are 
yearly infects, all over the world, out of which eight to ten 
million will develop the disease along their lives; a half of 
infected will present the contagious form and three million 
of them will die, every year (Freire, Bonametti, Matsuo, 
2007). The tuberculosis is one of the main causes of death 
for infectious diseases, being responsible for 1.6 million 
of deaths all over the world, in 2005. This situation is 
aggravating since de appearance of AIDS (WHO, 2007).
Brazil occupies the 13th place in the ranking of 22 
countries concentrating 80% of tuberculosis cases in the 
world. According to official data from the Ministry of 
Health, in Brazil there are, currently, about 50 million pe-
ople infected with the Koch bacillus, but without disease 
development; with a contamination of more than 1 million 
people every year, due to contact with sick persons. Yearly 
in Brazil, approximately, 111thousand new cases appear 
and 6 thousand deaths occur, being Rio de Janeiro the state 
with higher number of registered cases yearly, approxima-
tely 17,000; which corresponds to 20% of registered cases 
in the country (Souza, Vasconcelos, 2005). In the state of 
Rio de Janeiro, the disease was declared as priority since 
1999 and the Program of Tuberculosis Control was been 
working hardly in the last years, in order to reverse this 
picture (Secretaria, 2008).
The treatment of tuberculosis patients is done with 
short duration chemotherapy during six months, including 
isoniazid, rifampicin and pyrazinamide during the first 
two months, followed by isoniazid and rifampicin (Figure 
1) during the next four months. The use of these last two 
drugs is justified, based on their activity on the intracellular 
slow growing bacilli, as well as on those of intermittent 
growing present on caseous necrosis, which is essential for 
the successful sterilization of tissular lesions (Dalcolmo, 
Andrade, Picon, 2007).
The voltammetry technique is based on the study of 
potential-current curves (voltammograms) resulting from 
processes of electrons transference. These processes occur 
in the surface of a work electrode, always as a process of 
electrons transference (reduction or oxidation of electro-
chemically active species) is observed, as a function of 
applied potential.
The analytical importance of voltammetry is origina-
ted from two characteristics of obtained voltammograms. 
Firstly, the position of analytical signals respecting to 
applied potential could be utilized as a useful tool, in the 
identification of electroactive species. Secondly, under 
specific experimental conditions, the limiting current is 
governed by the concentration of electroactive species 
in the analyzed solution (Bard, Faulkner, 2001), which 
allows the use of this technique for quantitative analysis.
The electroanalytic methodology for the determi-
nation of isoniazid and rifampicin in the medications 
utilized for tuberculosis treatment was developed, uti-
lizing the differential pulse voltammetry. The isoniazid 
and rifampicin posses electroactive site and are reduced 
on the work electrode surface (Hanging Mercury Drop 
Electrode – HMDE).
Studies based in electroanalytical techniques are 
reported in the literature, as for the determination of iso-
niazid, as for the characterization of its electrochemical 
behavior. Lund (1963), employing the polarography, has 
evidenced that isoniazid presents, in acid medium, two 
reduction waves. The first one is attributed to amide group 
reduction, after transference of two electrons; the second 
corresponds to reduction of pyridinic ring involving the 
same number of electrons. Sulaiman and Hameed (1988) 
reported the determination of isoniazid and other hydra-
zides using the polarography of differential pulse, which 
was applied in the determination of a ternary mixing with 
other hydrazides. Rodrigues-Mellado et al. (1993) have 
studied the oxidation of isoniazid on mercury electrode, 
in a pH interval between 6 and 13. Angulo et al. (1993) 
reported that polarographic reduction of isoniazid is 
characterized by two waves in pH <9.5. The first one is 
referred to reduction of C=N binding present in the pyri-
dinic ring of the molecule and the second results from the 
reduction of hydrazide group, which leads to ammonia 
formation. Tong et al. (1997) described the voltammetric 
determination of isoniazid on vitreous carbon electro-
de. Ghoneim et al. (2003) reported the utilization of a 
procedure of voltammetry of adsorptive redissolution, 
employing a mercury electrode for the determination of 
isoniazid in pharmaceutical formulations and in biologic 
fluids. Wahdan (2005) and Liang et al. (2007) studied the 
voltammetric behavior of rifampicin oxidation, reporting 
that the mechanism involves the same typical number of 
electrons and protons as for hydroquinones.
Hammam et al. (2004), by adsorptive redissolution 
voltammetry, and Wahdan (2005), by cyclic voltammetry 
and linear scanning, developed methodologies for the de-
termination of isoniazid and rifampicin, in pharmaceutical 
formulations and biologic fluids, employing electrode of 
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carbon paste. Lomillo et al. (2001) reported the utilization 
of a mathematic model to obtain a voltammetric resolution 
of ternary mixings containing rifampicin, isoniazid and 
pyrazinamide, employing polarography of differential 
pulse.
In this sense, the proposal of this work was to de-
velop and validate an electroanalytical methodology for 
the determination of isoniazid and rifampicin drugs in the 
associated form in medications utilized for tuberculosis 
treatment, and evaluate the quality of these medications 
distributed in Rio de Janeiro state.
MATERIAL AND METHODS
Equipment and laboratory glasses
The voltammograms in differential pulse were 
registered utilizing the voltammetric system of Metrohm 
model 757 VA Computrace coupled to an electrochemical 
cell composed by three electrodes: hanging mercury drop 
electrode (HMDE) as work electrode, Ag/AgCl, KCl 
(3 mol/L) as reference electrode and platinum as auxiliary 
electrode.
All volumetric flasks and pipettes were calibrated.
Reagents and samples
All solutions were done utilizing ultrapure water 
from the Milli-Q system (Millipore).
All utilized reagents were of analytic grade (Merck).
The support electrolyte was the monoacid sodium 
phosphate 0.2 mol/L and citric acid 0.1 mol/L (buffer 
McIlvaine pH 7.0). 
The reference chemical substances isoniazid and 
rifampicin, utilized as standards, were obtained from 
Brazilian Pharmacopoeia.
Four lots of capsules of isoniazid and rifampicin (1, 
2, 3 and 4), coming from Laboratory A, were analyzed. 
According to this laboratory, such capsules contained 
200 mg of isoniazid and 300 mg of rifampicin. Two other 
lots (5 and 6) of tablets, from Laboratory B, were also 
analyzed. According to the package of lot 5, the content 
was 200 mg of isoniazid and 300 mg of rifampicin; and 
respecting lot 6, the content was 100 mg of isoniazid and 
150 mg of rifampicin.
The electroanalytical methodology for the determi-
nation of isoniazid and rifampicin, in medications utilized 
for tuberculosis treatment, was developed utilizing the 
differential pulse voltammetry.
The work, reference and auxiliary electrodes were 
the hanging mercury drop electrode (HMDE), Ag/AgCl, 
(KCl 3 mol/L) and platinum, respectively. 
The analytical curves were built adding in the 
electrochemical cell, 5 consecutive portions of 50 µL of 
isoniazid (50 mg/L) and rifampicin (80 mg/L) standards 
and varied amounts of buffer McIlvaine pH 7, in order 
to obtain the cell total volume of 10.0 mL. The final con-
centrations, therefore, were of 0.25, 0.50, 0.75, 1.00 and 
1.25 mg/L for the isoniazid and 0.40, 0.80, 1.20, 1.60 and 
2.00 mg/L for the rifampicin. The solution was deaired for 
5 minutes with nitrogen for the removal of oxygen and, 
next, static for some seconds before the step of scanning in 
the cathodic sense. Table I presents the optimized operatio-
nal parameters for determination of these active principles, 
in medication samples in form of tablets or capsules.
All measurements were done in 10.0 mL of solution 
and in triplicate, as in the analytical curve preparation, as 
in the analyzed samples.
The developed electroanalytical methodology was 
validated according the document of INMETRO (INME-
TRO, 2007). The evaluated parameters were: linearity 
(work range), detection and quantification limits, preci-
sion (repeatability and intermediate precision), accuracy 
(recovery) and robustness. For the parameter robustness, 
FIGURE 1 – Molecular structures of isoniazid (a) and rifampicin 
(b).
TABLE I – Experimental parameters for the determination of 
isoniazid and rifampicin in medicines by differential pulse 
voltammetry
Voltammetric Parameters Optimized Value
Initial potential -0.80 V
Final potential -1.20 V
Scanning velocity 10 mV/s
Pulse amplitude 50 mV
Balance time 5 s
Scanning direction cathodic (negative)
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electrolyte pH and scanning velocity were evaluated. The 
software Statistic 8.0® (Statsoft) was used to determine the 
limits of detection and quantification.
The methodology developed was also compared 
with the official method (high performance liquid chroma-
tography) professed in The United States Pharmacopeia 
(USP 31, 2008).
After the methodology validation, the determinations 
of associated isoniazid and rifampicin, in form of capsules 
and tablets medications produced by two Pharmaceutical 
Companies (A and B), were developed. The samples mass 
was calculated and weighted utilizing the parametric values 
professed by the manufacturers, and dissolved in 1 mL of 
methanol and buffer McIlvaine pH 7 within a volumetric 
flask of 50 mL, in order to locate the obtained concentration 
around the middle of analytical curve.
RESULTS AND DISCUSSION
The isoniazid and rifampicin were determined by 
differential pulse voltammetry, according to experimental 
conditions described at Table I. In the voltammogram of 
isoniazid, two peaks were found, meaning two different 
electroactive sites in the respective molecule, in -0.98 V 
and in -1.10 V; with the latter one presenting the higher 
current. Because of that, the peak in -1.10 V was chosen 
for the building of analytical curve. For the rifampicin, it 
was found a single peak around -0.90 V (Figure 2).
The work ranges were of 0.25 to 1.25 mg/L (y (na) = 
45.29 (mg/L) + 2.752; r2 of 0.9990) for the isoniazid (INH) 
and of 0.40 to 2.00 mg/L (y (na) = 12.64 (mg/L) – 0.9380; 
r2 of 0,9992) for the rifampicin (RIF).
To evaluate the two determination methods of 
associated isoniazid and rifampicin, Differential Pulse 
Voltammetry (DPV – our developed method) and high 
performance liquid chromatography (HPLC – official 
method – UPS 31, 2008) were used. The bilateral test F, 
with 95% of confidence interval and (F6.6) grades of liberty 
was applied. To express the results accuracy, the standard 
deviation and relative standard deviation of every conjunct 
of determinations referring to sample of lot 5, coming from 
Pharmaceutical Company B, were calculated. Through 
the obtained results, with was possible to verify that the 
methods do not present statistically significant differences 
and the calculated values for the relative standard devia-
tion were below 2% (Haswell, 1992), demonstrating so 
accuracy in both methods. For the calculations of isoniazid 
and rifampicin tenor in the analyzed medication, the values 
professed by its manufacturer were adopted. The method 
accuracy was evaluated by repeatability and intermediate 
accuracy (the same previous determinations, but in diffe-
rent days), as described at Table II.
The developed electroanalytical methodology was 
validated according the parameters described in the orien-
tation document from INMETRO (INMETRO, 2007). 
During the pH study, it was verified a cathodic 
displacement of peak potential with an increase of pH, 
as for INH, as for RIF; however, between the pH 6.5 and 
7.5 such displacements were practically absent. Respec-
ting to pH, the method was robust for this narrow pH 
range. The obtained validation results are described at 
Table III.
After the validation of developed electroanalytical 
method, the medication samples from Pharmaceutical 
Companies A and B containing isoniazid and rifampicin 
in the associated form, were analyzed taking as a base 
the analytical curves presented at Figure 2. The obtained 
results are described at Table IV.
FIGURE 2 – Voltammograms (a) and analytical curves (b) of INH (¿) 0.25; 0.50; 0.75; 1.00 and 1.25 mg/L and of RIF (p) 0.40; 
0.80; 1.20; 1.60 and 2.00 mg/L with buffer McIlvaine pH 7.0 as support electrolyte, in the conditions described at Table I.
Development and validation of an electroanalytical methodology for determination of isoniazid and rifampicin 335
TABLE II – Comparison of ‘high performance liquid chromatography’ and ‘differential pulse voltammetry’ methods for determination 
of both, isoniazid and rifampicin, associated into a pharmaceutical formulation
Method of 
determination
Tenor (%) * Repeatability RSD (%) Intermediate 
Accuracy RSD (%) 
(n=14)
First day (n=7) Second day (n=7) First day (n=7) Second day (n=7)
ISONIAZID
HPLC 98.4 ± 0.2 98.0 ± 0.1 0.4 0.3 0.5
DPV 97.6 ± 0.3 98.2 ± 0.2 0.6 0.7 0.7
RIFAMPICIN
HPLC 97.0 ± 0.4 97.6 ± 0.3 0.8 0.9 1.1
DPV 96.4 ± 0.5 96.8 ± 0.5 0.6 0.7 0.9
* Composition of formulation: 200 mg/capsule of isoniazid and 300 mg/capsule of rifampicin.
TABLE III – Evaluated parameters in the validation of electroanalytical methodology, according to document of INMETRO, 2007
Evaluated parameters Found results
Isoniazid Rifampicin
Linearity (work range) (0.25 - 1.25) mg/L (0,40 – 2,00) mg/L
Detection limit 0.05 mg/L 0,07 mg/L
Quantification limit 0.14 mg/L 0,19 mg/L
Recovery 98.2 ± 0.4 % 95,8 ± 0,6 %
Robustness respecting to pH pH between 6.5 e 7.5
TABLE IV – Results found in medications from Pharmaceutical Companies A and B, using differential pulse voltammetry, under 
the conditions described at Table I
Sample (Lot) (*) Pharmaceutical 
Company
Isoniazid Rifampicin
Recovery (%) 
(n=7)
Accuracy RSD 
(%)
Recovery (%) 
(n=7)
Accuracy RSD 
(%)
1 A 96.1 ± 0.8 1.3 94.3 ± 0.7 1.0
2 A 94.2 ± 0.4 1.0 89.0 ± 0.9 1.4
3 A 98.3 ± 0.6 1.1 91.7 ± 0.6 1.2
4 A 100.9 ± 0.5 0.5 101.0 ± 0.8 0.2
5 B 97.6 ± 0.6 0.8 96.4 ± 0.9 1.4
6 B 98.4 ± 0.8 1.1 96.7 ± 0.9 1.3
* Values professed by manufactures: Lots 1, 2, 3 and 4 - 200 mg of isoniazid and 300 mg of rifampicin per capsule. Lot 5 - 200 mg 
of isoniazid and 300 mg of rifampicin per tablet. Lot 6 - 100 mg of isoniazid and 150 mg of rifampicin per tablet.
To evaluate the obtained results of isoniazid and 
rifampicin tenors in the analyzed samples, the acceptable 
ranges at USP 31, of 90 to 110% for isoniazid and 90 to 
130% for rifampicin, both respecting to the value profes-
sed by manufacturer, were consulted.
Both, as the samples from Pharmaceutical Company 
A, as those from Pharmaceutical Company B, presented 
satisfactory results respecting the isoniazid tenor. For the 
rifampicin tenor, only one sample (Lot 2) presented a non-
satisfactory result.
CONCLUSIONS
Although the technique professed at The United 
States Pharmacopeia (USP 31) for the determination of 
isoniazid and rifampicin in medications is high perfor-
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mance liquid chromatography, such active principles could 
also be determined through differential pulse voltammetry 
(DPV), the technique developed and validated in this 
work.
Through the electroanalytical methodology, it was 
possible to determine simultaneously the isoniazid and 
rifampicin. The method was validated, being obtained 
satisfactory results, and presenting some advantages 
respecting to official method (USP 31), such as lower 
analysis time (approximately three times lower), operation 
practicability of equipment, higher easiness in preparation 
of samples and standards, and analyses cost estimated as 
approximately three times lower.
Respecting to voltammetric methods employing 
electrode of carbon paste, the proposed method presents 
better repeatability, due to perfect reproduction in the 
formation of mercury drop at every determination.
All the evaluated parameters are compatible with 
the recommendations established at the INMETRO docu-
ment of orientation for validation, and the methodology 
could be utilized for quantitative and routine analyses of 
pharmaceutical formulations containing isoniazid and 
rifampicin in the associated form, in the format of both, 
tablets and capsules. 
According to USP 31, the acceptability ranges for 
tenors of isoniazid and rifampicin are of, respectively, 90 
to 110% and 90 to 130% of the value professed by manu-
facturer. Out of the all samples analyzed, only a single 
lot from Pharmaceutical Company A presented a result 
below the range described at USP 31 for rifampicin. For 
isoniazid, all obtained results were satisfactory.
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